Edwards Lifesciences (EW) financials
Edwards Lifesciences revenue and earnings by year
Edwards Lifesciences's revenue was $6.07 billion in the fiscal year to December 31, 2025, up 11.5% from the year before. Net income was $1.07 billion, 17.7% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 8.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.07 | 5.44 | 5.01 | 4.46 | 5.23 | 4.39 | 4.35 | 3.72 | 3.44 | 2.96 |
| Revenue growth | 11.5% | 8.6% | 12.2% | -14.7% | 19.3% | 0.9% | 16.8% | 8.4% | 15.9% | — |
| Gross profit | 4.73 | 4.32 | 4.03 | 3.74 | 3.98 | 3.31 | 3.23 | 2.78 | 2.56 | 2.17 |
| Gross margin | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% | 75.4% | 74.4% | 74.8% | 74.5% | 73.1% |
| Operating income | 1.10 | 1.38 | 1.28 | 1.46 | 1.57 | 0.91 | 1.15 | 0.74 | 1.03 | 0.75 |
| Operating margin | 18.2% | 25.3% | 25.6% | 32.8% | 29.9% | 20.8% | 26.4% | 19.9% | 30.0% | 25.4% |
| Net income | 1.07 | 4.17 | 1.40 | 1.52 | 1.50 | 0.82 | 1.05 | 0.72 | 0.58 | 0.57 |
| Net margin | 17.7% | 76.7% | 28.0% | 34.1% | 28.7% | 18.8% | 24.1% | 19.4% | 17.0% | 19.2% |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.12 | $0.90 | $0.87 |
| Free cash flow | 1.34 | 0.29 | 0.64 | 0.97 | 1.41 | 0.65 | 0.93 | 0.69 | 0.83 | 0.53 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open EW in Markets.
How Edwards Lifesciences makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.26B | 72.3% |
| Surgical | $284M | 16.3% |
| Transcatheter Mitral & Tricuspid Therapies | $199M | 11.4% |
See also: EW valuation and P/E history · EW returns
No forecast, no recommendation. This page describes Edwards Lifesciences from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.